Novo Nordisk's big obesity ambitions take shape with semaglutide win

14th May 2020 Uncategorised 0

On the heels of showing its popular diabetes med semaglutide holds potential in non-alcoholic steatohepatitis, Novo Nordisk is now touting the first clinical win for the GLP-1 med in obesity—a tough market it’s bet big on.

More: Novo Nordisk's big obesity ambitions take shape with semaglutide win
Source: fierce